New cancer drug BTM-3566 enters first human tests

NCT ID NCT07266285

Recruiting now Disease control Sponsor: Bantam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called BTM-3566 in 30 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and understand side effects. Participants take the drug for 7 days on and 7 days off, and researchers will also look for any signs that the drug shrinks tumors or slows cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BTM-3566
What this could lead to: If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 30 participants, so the drug may not prove effective or may have serious side effects. It is too soon to know if it will work in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

NEXT Houston
RECRUITING

Houston, Texas, 77054, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.